













































Recent findings from evolutionary genomic studies 
have stimulated a rethinking of brain energy 
metabolism and the role it plays in brain function [1]. 
These findings indicate a significant enrichment in the 
expression of genes involved in energy metabolism in 
the human brain when  compared  to  other  (nonhuman)  
 
 













































primates [2, 3]. The high metabolic cost of the human 
brain, reaching 20% of the whole body energy 
consumption, is related to the emergence of higher 
cognitive functions [4, 5].  
 
Several functional neuroimaging surveys provide 
evidence that the brain is particularly vulnerable to 
alterations in energy homeostasis, a trait derived from 



























Abstract:  Brain  function  is  highly  dependent  upon  controlled  energy  metabolism  whose  loss  heralds  cognitive
impairments. This is particularly notable in the aged individuals and in age‐related neurodegenerative diseases. However,
how  metabolic  homeostasis  is  disrupted  in  the  aging  brain  is  still  poorly  understood.  Here  we  performed  global,
metabolomic and proteomic analyses across different anatomical  regions of mouse brain at different stages of  its adult
lifespan. Interestingly, while severe proteomic imbalance was absent, global‐untargeted metabolomics revealed an energy
metabolic  drift  or  significant  imbalance  in  core  metabolite  levels  in  aged  mouse  brains.  Metabolic  imbalance  was
characterized by compromised cellular energy status (NAD decline, increased AMP/ATP, purine/pyrimidine accumulation)
and  significantly  altered  oxidative  phosphorylation  and  nucleotide  biosynthesis  and  degradation.  The  central  energy
metabolic drift suggests a failure of the cellular machinery to restore metabostasis (metabolite homeostasis) in the aged
brain and therefore an  inability to respond properly to external stimuli,  likely driving the alterations  in signaling activity
and thus in neuronal function and communication. 
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its oxidative, high-energy demanding metabolism [1, 6, 
7]. In vivo monitoring of brain metabolism, using PET 
(Positron Emission Tomography) and MRS (Magnetic 
Resonance Spectroscopy), have reported an energy 
deficit determined by abnormally low glucose 
metabolism (uptake and oxidation) coupled to 
mitochondrial dysfunction as one of the main, early 
indicators of age-related changes toward cognitive 
impairment in the healthy aging brain and 
neurodegenerative diseases [8-10].  
 
Glucose is the primary source of energy for brain cells 
where it is almost fully oxidized via oxidative 
phosphorylation in the mitochondria to produce ATP 
[11]. Although glucose is a key energetic substrate for 
the brain, the alternative substrates such as lactate and 
ketone bodies are used when glucose is in short supply 
[12, 13]. While neurons require extensive amounts of 
energy for signaling processes the astrocytes play an 
essential role in the regulation of brain energy 
metabolism [1]. Energy metabolism is coordinated 
through the mitochondria-cytosol link, and the observed 
cerebral glucose hypometabolism driven by 
mitochondrial regulatory dysfunction seems to be an 
early event in the progression of brain aging that 
hinders the maintenance of cellular homeostasis. 
Disrupted ion homeostasis, inability to maintain the 
integrity of cellular compartments, synaptic 
communication and neuro-transmission directly affects 
neural function [14, 15]. Although the impairment of 
mitochondrial energy-transducing capacity leading to 
loss of cellular homeostasis is an evolutionary 
conserved phenomenon considered a hallmark of aging, 
it is still largely unknown why and how the homeostasis 
is disrupted [16, 17]. Brain aging is a particularly 
challenging problem to assess and it is not clear whether 
the mechanisms that have been identified in different 
animal models (including rodents, flies, molluscs and 
worms) at the organism level also play a role in central 
nervous system (CNS) aging.  
 
With the ‘omic technology improvements we are 
getting closer to understanding the causes and effects of 
aging at the molecular level. Genome- and proteome-
wide views of age-associated changes in the epigenome, 
in gene and protein expression, have been described in 
the aging brain in animal models and across human 
populations [18-23]. However, metabolome-wide 
studies are scarce and mainly focused on biofluid 
screening (e.g. blood plasma, cerebrospinal fluid) for 
biomarker discovery associated with neurodegenerative 
diseases that implicate accelerated disease-induced 
aging. Molecular phenotyping at the metabolite level 
during the aging process has been limited to a small 
subset of known highly abundant metabolites (e.g. 
glucose, lactate, N-acetyl aspartate (NAA), myo-
Inositol, creatine, choline, glutamate and glutamine) 
that can be assessed in vivo, using PET and MRS [8, 
24]. Low sensitivity of MRS and PET provide limited 
information concerning low abundant and labile 
metabolites. Global tissue metabolomics could 
markedly upgrade our understanding of the molecular 
bases of brain aging by direct and unbiased monitoring 
of tissue activity across a broad range of small 
molecules, including low abundant and trace 
metabolites, from the whole-organ level down to the 
regional, cellular and sub-cellular level [25, 26]. 
Specific types of cells (e.g. cell culture) and/or fractions 
enriched in specific organelles (e.g. mitochondria) can 
be routinely analyzed due to considerable advancements 
in instrument sensitivity.  
 
Here we examine brain energy metabolism in order to 
characterize the role it plays in central nervous system 
function during the healthy aging process. In mice, as in 
humans, aged individuals have shown a variety of 
cognitive and behavioral changes, including deficits in 
learning and memory [27, 28]. While most studies have 
addressed changes in energy metabolism of the aging 
brain in pathological conditions, in the current study we 
have applied cutting-edge, mass spectrometry-based 
‘omic technologies to reveal metabolic changes that are 
taking place during the normal brain aging. The 
proteome and metabolome wide profiling of mouse 
brain at different stages of the life cycle (12, 18 and 24 
months) and across different anatomical regions 
provided insight into a new phenomenon we define as 
metabolic drift in the aging brain. The intrinsic changes 
in cellular activity of a healthy aging brain were mainly 
defined by altered oxidative phosphorylation and 
nucleotide biosynthesis and degradation, with some 
parallels to metabolic reprogramming in cancer. 
Characterization of the aging brain phenotype at the 
metabolite level is an essential step toward 
understanding how metabostasis is changing and thus 




Quenching brain energy metabolism 
 
Prior to global metabolomic and proteomic analyses, 
and to allow for sensitive, brain energy metabolism 
investigation, focused beam microwave irradiation 
(FBMI) was applied to the mice to induce instant 
euthanasia, simultaneously halting enzymes and 
quenching the metabolic activity in the brain tissue (see 
Supplemental Experimental Procedures for detailed 
explanation). FBMI allowed for the preservation of 
brain tissue, facilitating brain tissue isolation and 
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dissection. The effectiveness of FBMI has been 
validated with characterized 1H-MRS metabolite 
relationships (low lactate, high NAA) from postmortem 
tissue followed by proteomic and metabolomic analyses 
(Figure S1) [29]. Thus, the brain proteome and 
metabolome was preserved from degradation and/or 
transformation during the post-mortem delay.  
Untargeted proteomic analysis was performed first at 
two ages, 12 months old (middle aged) and 24 months 
old (aged) mice. Following the indications from 
hippocampal proteome analysis the comprehensive 
metabolomic profiling of central carbon metabolism 
was performed in the hippocampus and two additional 
brain regions at these two ages as well as at an 
intermediate time point, 18 months of age (Figure 1). 
Water soluble, central carbon metabolites, including 
energy currency metabolites, were examined by 
untargeted profiling using hydrophilic interaction 
chromatography in basic conditions coupled to negative 
electrospray ionization tandem mass spectrometry 
(HILIC –ESI-MS/MS).  
 
Quantitative analysis of the aging hippocampal 
proteom e implicates metabolic dysfunction 
 
Initially, the proteome wide study of the hippocampus 
was performed due to its known importance in learning  
and memory, functions that can decrease with age. 
SWATH-MS proteomics was used to examine the 
hippocampal proteome. In total, 1,925 proteins were 
quantified in all specimens (six independent biological 
replicates where each hemisphere was analyzed 
separately) from 12 and 24 month old groups. Overall 
the majority of the 1,925 proteins were not altered with 
age in the hippocampus. The distribution of the log2 
(24-/12-month) protein expression values revealed that 
16.4 % of the total proteome experienced a change 
greater than 1.4 fold (2±0.5) with 112 and 204 proteins 
showing decreased or increased expression with age, 
respectively (Figure 2A and 2B, Table S1). Of the 1,925 
proteins, 6.5% of proteins (126) were determined to be 
significantly differentially expressed (PPDE ≥ 0.95 and 
BH ≤ 0.05) between 12- and 24-months of age using a 
Bayes-regularized t-test and multiple hypothesis testing 
corrections (Table S2).  
 
The functional assessment of the 126 hippocampal 
proteins exhibiting altered expression with age using the 
PANTHER Classification System revealed that the 
largest group of differentially regulated proteins (24) 
identified enrichment of the Gene Ontology (GO) 
biological process term nucleobase-containing 
compound metabolic process, encompassing cyclic 
nucleotide, purine, pyrimidine, DNA and RNA 
metabolic processes (Table S2). Further interrogation of 
the metabolic pathways representative of these 126 
proteins using Ingenuity Pathway Analysis (IPA) 
revealed that energy currency metabolites and the 
subunits of biological molecules such as nucleic acids 
and proteins may be altered with age, thus implying the 
differences in relative utilization of amino acids, 
purines, and pyrimidines with aging in the hippocampus 
Figure 1.  Experimental design of  comprehensive  regional
and  temporal  profiling  of  murine  brain  proteome  and
metabolome. Prior to brain sample collection the Focused Beam
Microwave  Irradiation  (FBMI)  was  applied  as  a  metabolism
quenching  technique  to  inactivate  the  enzymes  and prevent  the
metabolite  degradation  during  the  post‐mortem  delay  (See  also
Figure S1).  Initially the hippocampus was dissected and extracted
for  proteome  profiling  using  nano  SWATH‐MS  –  nano  flow  data
independent  tandem  mass  spectrometry  acquisition  mode  with
variable  windows  to  facilitate  protein  quantification.  As  the
altered hippocampal proteome  implied  the  changes  in metabolic
processes,  the  metabolome  profiling  was  performed  on  three
different brain regions using micro HILIC‐DDA‐MS – capillary  flow
hydrophilic  interaction  chromatography  coupled  with  data
dependent  tandem  mass  spectrometry  acquisition  mode  to
facilitate metabolite identification.  
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(Figure 2C, Figure S2). Overall the proteomic changes 
in the hippocampus with aging highlighted alterations in 
mechanisms that have direct impact on the regulation of 
metabolic processes, particularly nucleobase-containing 
metabolites.   
 
Untargeted metabolomics reveals energy metabolic 
drift in aged mouse brain 
 
To characterize the metabolic changes of the healthy 
aging brain, untargeted metabolomic profiling of 
hippocampal tissue as well as two additional regions, 
frontal cortex and caudoputamen was performed at three 
different stages (12, 18 and 24 months, approximately 
equivalent to 42, 55 and 69 years in human [46]) of adult 
mouse lifespan. Using untargeted metabolomics, 818 
dysregulated metabolite features (p < 0.01, q < 0.001, Int 

































comparing these three different life stages (6 specimens x 
3 brain regions at each time point). After removing the 
chemical and bioinformatic noise, and redundant isotope, 
adduct, and ion-source fragment features the majority of 
the putatively identified altered metabolites were 
associated with the following groups of central core, 
water soluble metabolites: purines and pyrimidines, 
amino acids, nucleosides, nucleoside phosphates and 
redox-electron carriers (see cloud plot in Figure 3A). 
Among brain lipids, three different sulfatides (from C18 
to C24), a major lipid components of myelin sheath, 
showed a progressive decrease pattern with age (Figure 
S4). Depletion of myelin-associated glycosphingolipids 
has been observed to occur upon aging and can be ex-
plained by the anatomical changes in neurons including a 
segmental demyelination. These changes have a negative 
impact on neuronal plasticity, specifically the information 

































Figure 2. Hippocampal proteomic changes from 12 to 24 months. The histogram distribution of  the  log2  (24‐/12‐month) protein
ratios for the (A) total 1,925 quantified proteins and (B) 126 significantly differentially expressed proteins. (C): Bar graph of overrepresented
pathways  (p  <  0.05)  based  on  the  protein  list  of  differentially  expressed  proteins  (from  12  to  24 months,  126  proteins  from  the  Bayes‐
regularized  t‐test and multiple hypothesis  testing corrections). The upregulated and downregulated  refer  to  the percentage of proteins up
(increased expression in 24 compared to 12 months) or downregulated (decreased expression in 24 compared to 12 months) in each pathway. 
  























































































Figure  3.  Metabolic  changes  and  associated  affected  pathways  in  aged  mouse  brain  using  global  metabolomic




MS)  is  shown  in  the  background.  (B)  Predicted metabolic  activity  network  in  healthy  aging  brain  directly  from m/z  feature  table.
Network  is  defined  by  4  subnetworks  or  modules  represented  by  glutamate,  AMP,  NAD  and  GDP‐GTP  that  show  more  internal
connections  than  expected  randomly  in  the  whole  network.  Metabolites  are  colored  according  to  their  p‐values  and  intensities
represented above  in the cloud plot. Not significantly altered metabolites are represented by transparent bubbles and were  included
for network connectivity. (C) Metabolite set enrichment analysis (MSEA) for mammalian species based on a library containing 88 groups
of  biologically meaningful metabolite  sets. Pathways  are  ranked  depending  on  the  overlap  of  identified  significantly  dysregulated
metabolites (IDs validated by MS/MS analysis) and total metabolites present in the reference pathway (Table S6).  
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The disruption of central core metabolism was further 
explored via network modelling and pathway 
enrichment analysis. Overall 50 discriminating 
(significantly altered) central core metabolites were 
identified (using retention time and MS/MS matching as 
demonstrated in Figure S5) and displayed as readout of 
the aging brain phenotype (Figure 3B and 3C). The 
affected metabolic network as a function of age, across 
all three different brain regions was defined by 4 
interacting modules represented by glutamate, AMP, 
NAD and GDP-GTP. KEGG pathway mapping and 
metabolite set enrichment analysis for mammalian 
species highlighted the altered purine and pyrimidine 
metabolism, and central energy pathways, including 
glycolysis and oxidative phosphorylation, as well as a 
few signaling pathways such as adenosine receptor 
signaling, neural signaling through HTR and serotonin 
and insulin signaling (Figure 3C).  
 
Following the recently discovered phenomenon of 
transcriptional drift in several different model organisms 
(including C. elegans, mouse and human) [31], the total 
dysregulated metabolome data set was further mined. A 
trend, consistent with transcriptional drift, was revealed 
in our metabolomic data set and named accordingly as a 
metabolic drift or significant imbalance in metabolite 
levels in the aged brain when compared to the adult 
reference stage (Figure 4). Metabolic imbalance in the 
aged mouse brain was observed in the increased variance 
of fold changes for the total set of dysregulated 
metabolites across all three brain regions (hippocampus, 
cortex, and caudoputamen), without significant 
difference between regions. (Figure 4A). This increased 
drift-variance among metabolites within the biological 
replicates reflects the observed changes of metabolite 
levels in opposing directions, as shown in the heat map in 
Figure 4B. Although the deviation away from levels 
measured in adult reference stage increases with age the 
metabolic drift in not about the amplitude of variation per 
metabolite. The metabolic drift has been calculated 
across the whole pool of affected metabolites, reflecting 
the variations in opposing directions within the entire 
metabolite pool and within the same specific pathways. It 
describes how far the levels of specific metabolites in the 
aged brain (within the same pathway) have been 
significantly down-regulated whereas others were 
significantly up-regulated. The observed changes in 
opposing directions result in loss of biochemical balance 
among metabolites within specific functional subsets or 
biological pathways leading to their disruption and 
functional decline with age. Age-associated changes in 
the expression of metabolic enzymes (Figure S2) as well 
as oxidative modifications that alter enzyme-kinetics also 
contribute to increasing metabolite imbalance. 
 
Metabolic drift mapped onto biological pathways 
 
 Metabolic drift was primarily identified with metabolites 
involved in central carbon pathways, the changes that 
were validated by targeted quantification of identified 
altered metabolites and interconnected pathways. 
Pathway mapping of the dysregulated metabolites high-
lighted altered energy metabolism, including oxidative 
phosphorylation, glycolysis and nucleotide biosynthesis 
and degradation. Compromised cellular energy status was 
marked by NAD decline, increased AMP/ATP ratio and 
significant imbalance in nucleotide biosynthesis and 
degradation pathways. This significant drift in nucleotide 
metabolism was reflected in the accumulation of purines, 
pyrimidines, nucleosides and nucleoside monophosphates 
and depletion of nucleoside tri-phosphate levels (Figure 
5, Figure S6). Interestingly, the TCA cycle was not 
dysregulated and mitochondrial dysfunction appears to be 




In this model of brain aging, we have found evidence for 
a compromised central energy metabolic state, as well as 
changes in nucleotide biosynthesis and degradation. This 
was reflected in the significant metabolite variations in 
opposing directions, within the entire metabolite pool and 
within the specific metabolic pathways. The observed 
phenomenon can be characterized by loss of normal 
homeostatic mechanisms, and termed drift-variance. In 
physiological terms, this drift-variance can be explained 
as an increasing deviation as homeostasis control is 
diminished, essentially a failure to maintain steady state 
levels following a response to external stimuli. These 
findings are consistent with the theory of metabolic 
stability of regulatory networks, which claims that the 
capacity of cells to maintain stable concentrations of 
critical metabolites (including reactive oxygen species) is 
a prime determinant of life span [32, 33]. According to 
this theory and our observations of metabolic drift in the 
aged brain, the capacity of cells to respond appropriately 
to stimuli of internal or external origin by successfully 
moving back to the metabostasis could be a critical factor 
in the regulation of longevity of brain function [31, 33]. 
We also note an increased variability in the metabolite 
levels in the oldest mice, consistent with the increased 
variability found in a number of physiological parameters 
including cognitive processes [34]. 
 
It has been demonstrated that the imbalance in oxidative 
phosphorylation (NAD decline, increased AMP/ATP 
ratio) leads to impaired mitochondrial electron transfer 
and active respiration thus causing the decrease in mito-
chondrial energy-transducing capacity. 
  
















































































































blue colored boxes  imply significant metabolite depletion and red colored boxes  imply significant metabolite  increase
or accumulation. Additional changes indirectly related to the above presented pathways are shown in Figure S6. Non‐
significant changes are represented  in grey tones. Box and whisker plots display the  full range of variation  (whiskers:
median with minimum _ maximum; boxes: interquartile range). Y‐axis is represented as a log10 of metabolite area.  
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Compromised mitochondrial energy metabolism 
significantly affects neuronal activity and plasticity. 
Functionally, loss of neuronal plasticity or failure to 
adapt to decline in energy metabolism is viewed as a 
hallmark of age-related neurodegenerative diseases and 
directly associated with the age-dependent cognitive 
decline. This is one of the main reasons why brain 
energy metabolism is revisited in many ongoing 
physiology and behavioral studies. A gradual decline in 
energy metabolism during aging has been demonstrated 
by several functional neuroimaging techniques (Lin and 
Rothman 2014, Yin et al. 2014). PET scanning in aging 
mice revealed decreases in the cerebral metabolic rate 
of glucose, and proton (1H) MR spectroscopy (MRS) in 
the same animals revealed decreases in energy 
metabolites, correlated with decreases in spatial 
working and reference memory [35]. 
 
The hippocampal proteomic analysis implicated 
alterations in nucleobase-containing metabolites and 
revealed potential mechanisms behind such metabolic 
alterations. The nucleoside diphosphate kinases that 
play a major role in the synthesis of nucleoside 
triphosphates other than ATP from nucleoside 
diphosphates were determined to be significantly 
downregulated (Nme3, log2 = -1.2 and Nme4, log2 = -
2.6) within the hippocampus of 24- compared to 12-
month old mice, consistent with the observed lower 
levels of the triphosphate forms of these purines and 
pyrimidines. Further, increased expression of guanylate 
cyclase 1, soluble, beta 3 (Gucy1b3, log2 = 1.9), which 
catalyzes the conversion of GTP to cGMP would be 
expected to contribute to the decreased levels of GTP. 
The proteomics data also revealed decreased expression 
of   the   purine  recycling  enzyme   hypoxanthine 
phosphoribosyltransferase 1 (Hprt1, log2 = -0.5) with 
age within the hippocampus, consistent with altered 
purine metabolites. Alterations in AMP, ADP and ATP 
may be related to changes in the ATPase components 
Atp1b2 (log2 = 0.5) and Atp2b1 (log2 = -0.4), as well as 
Adenylate kinase 4 (Ak4, log2 = -1.2). 
 
Our proteomics data revealed decreased expression of 
Sirt3 in the hippocampus of older animals, which is 
consistent with the metabolomics observation of 
decreased ATP levels. Studies in Sirt3 knockout animals 
revealed reduced ATP levels as well as inhibited complex 
I activity [36]. Further, Sirt3 regulates the activity of 
acetyl-CoA synthetase 2, an important mitochondrial 
enzyme involved in generating acetyl-CoA for the TCA 
cycle [37]. Thus, loss of Sirt3 protein may contribute to 
the lower acetyl-CoA levels as well. In addition to loss of 
Sirt3 protein levels, our metabolomics data suggests that 
the activity of Sirt3 would be reduced since NAD, which 
was determined to be lower, is required for its activity. 
While we examined three different brain regions, there 
are multiple cell types present within each region 
(neurons, astrocytes, oligodendrocytes, microglia). The 
existence of functionally complementary metabolic 
profiles in two previously studied cell types, neurons 
and astrocytes, has already been identified in early 
neurochemical studies in the 1950s and 1960s [38]. 
Neurons utilize most of the energy in the brain [39, 40] 
and express high oxidative capacity [41]. In contrast, 
astrocytes, although capable of oxidative 
phosphorylation, predominantly process glucose glycol-
lytically and shuttle energy substrates, lactate and 
pyruvate to neurons for use in oxidative 
phosphorylation [1, 42]. While this shuttle has 
considerable experimental support there are also 
experiments indicating that glucose uptake by neurons, 
not astrocytes, provides the fuel for neuronal oxidative 
phosphorylation [43, 44]. Thus our findings have 
parallels to metabolic reprogramming (Figure 5), and 
can be interpreted either as occurring within the neuron, 
or in light of the astrocyte shuttle model instead of 
within a single cell, involving the astrocyte and the 
neuron pair within brain tissue, with the astrocyte 
supplying increased glycolytic substrates to the neuron 
to compensate for disrupted oxidative energy 
production with age (decreased oxidative 
phosphorylation) and meet the metabolic requirements 
of brain. In this model, the balance within individual 
cell types, however, can become lost, leading to what 
we term metabolic drift or altered relative metabolite 
stoichiometry.  
 
Steady state isotopic experiments combined with 
metabolomic profiling of different cell types (shift in 
population balance between astrocytes vs. neurons) and 
sub-cellular fractions (e.g. mitochondrial fraction and/or 
synapses) would offer a more complete understanding 
of the observed drift phenomenon. These global-
untargeted isotope-assisted experiments would be 
especially useful to trace the isotope enrichment across 
the broad range of metabolites in order to determine the 
directionality of the observed changes and pathway 
contribution in the utilization of specific substrates, 
such as 13C labeled glucose for example. In addition, 
the recently developed global metabolomic approach of 
arteriovenous blood analysis [45] could yield direct and 
real time insight to the aging brain. 
 
MATERIALS AND METHODS 
 
Sample collection. Male mice (C57BL/6) were obtained 
from the National Institute on Aging rodent colonies 
according to annotation standards for age classification 
[46]. All protocols were implemented in accordance 
with NIH guidelines and approved by the Institutional 
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Animal Care and Use Committee at the College of 
Medicine, University of Nebraska Medical Center. All 
animals were housed in a controlled room with a 
constant 12- hour light/dark cycle. Animals were fed 
NIH31 diet ad libitum while housed at the NIA and one 
month before sacrifice were shipped to UNMC where 
they were fed Harlan #7912 irradiated rodent chow ad 
libitum. Focused beam microwave irradiation (FBMI) 
was applied (following brief exposure to 1.5% 
isoflurane for anesthetic induction) in mice to deliver 
instantaneous euthanasia and quench the metabolism 
efficiently prior to brain dissection. As a “quality 
control” the 1HRMS spectra were acquired in the central 
brain region in order to screen brains for further 
analysis. The appearance of a large lactate peak was the 
primary criterion for sample exclusion from further 
metabolomic and proteomic analysis, as is shown in 
Figure S1 (for detailed description of FBMI procedure 
please see Supplemental Information).   
 
Metabolite and protein extraction. Dissected brain 
regions (hippocampus, caudoputamen, and frontal 
cortex) were extracted using a MeOH:H2O (4:1, v/v) 
solvent mixture as a best compromise to precipitate 
proteins and efficiently extract water-soluble and lipid 
metabolites. A volume of 500 μL of cold solvent was 
added to 10 mg of tissue, vortexed for 30 s and 
incubated in liquid nitrogen for 1 min. The samples 
were then allowed to thaw at room temperature and 
sonicated for 5 min. This cycle of tissue disruption was 
repeated two times for three rounds total. To precipitate 
proteins the samples were incubated for 1 hour at -20° 
C, followed by 15 min centrifugation at 17,000 x g at 4° 
C. The resulting supernatant was removed and 
evaporated to dryness in a vacuum concentrator. The 
protein pellets were evaporated to dryness in a vacuum 
concentrator and lysed in 100 mM Tris-HCl with 4% 
(w/v) SDS and 0.1 M DTT, pH 7.6 using brief 
sonication and incubation at 95° C for 5 min. The Pierce 
660 nm Protein Assay (Thermo Scientific) was used to 
determine protein concentration, as a reference for 
metabolite reconstitution. The dry metabolome extracts 
were reconstituted in ACN:H2O (1:1, v/v) normalized by 
the sample’s protein level, sonicated for 30 sec, and 
centrifuged 15 min at 13000 rpm and 4° C to remove 
insoluble debris. The supernatants were transferred to 
HPLC vials and stored at -80° C prior to LC/MS analysis.  
 
Proteome analysis. The protein lysates from the 12- and 
24-month old mouse hippocampus were analyzed using 
SWATH-MS Data Independent Acquisition (DIA), 
following the library generation (for detailed description 
of spectral library creation please see Supplemental 
Information). Prior to DIA mass spectrometry analysis, 
the protein lysates (50 μg) from the mouse hippocampus 
were digested with trypsin using the FASP method [47]. 
The resultant peptides were desalted using Oasis MCX 
cartridges and then quantified using the Scopes method 
[48]. The unfractionated samples of peptides (2 μg) 
from the 12- and 24-month old mouse hippocampal 
lysates for each brain hemisphere (right and left) were 
analyzed in sextuplet (six biological replicates per age 
group) using SWATH-MS DIA. LC-MS/MS was 
conducted using an AB SCIEX TTOF mass 
spectrometer coupled with an Eksigent NanoLC-Ultra 
1D plus and nanoFlex cHiPLC system (Eksigent). 
Samples were loaded onto a 75 μm x 0.5 mm ChromXP 
C18-CL 3 μm 120 Å trap column (Eksigent), washed 
with 98:2 HPLC water with 1% FA for 10 minutes and 
then eluted through a 75 μm x 15 cm ChromXP C18-
CL 3 μm 300 Å analytical column (Eksigent) at 300 
nL/min with 98:2 HPLC water with 1% FA using a 90 
minute linear gradient of 0-60% ACN with 1% FA. 
Autocalibration of spectra occurred after acquisition of 
every 4 samples using dynamic LC-MS and MS/MS 
acquisitions of 25 fmol β-galactosidase. Experimental 
samples (hippocampal peptides) were subjected to 
cyclic DIA of mass spectra using 25 Da swaths in a 
similar manner to previously established methods [49].  
 
Proteome data processing and analysis. All of the 
fragment ion chromatograms were extracted and 
automatically integrated with PeakView (v.2.1 Beta). 
The raw peak areas as reported by PeakView were used 
for all the quantification calculations with no data 
processing (either de-noising or smoothing) of any kind 
applied to the extracted ion chromatograms. To 
calibrate retention times, synthetic peptides 
(BiognoSYS) were spiked-in the samples in accordance 
with previously published work [50], we selected 5 
peptides and 5 transitions for quantitative analysis and 
targeted data extraction for each peptide was performed. 
Briefly, for each peptide the fragment ion 
chromatograms were extracted using the SWATH 
isolation window set to a width of 10 min and 50 ppm 
accuracy for quantification purposes in accordance with 
previously established protocols [49, 50]. Samples were 
normalized to the median peak ratios using MarkerView 
software (v.1.2.1.). The Pearson’s correlation 
coefficient, r, between the right and left hemisphere for 
each mouse was calculated revealing strong correlation 
at both ages (average r = 0.93 (12 mo) and 0.97 (24 
mo)) demonstrating the ability to quantify proteins from 
the hippocampus following FBMI with great precision. 
For subsequent analyses, the protein values for each 
hemisphere were averaged for each mouse. We also 
found strong correlation between biological replicates 
(average r = 0.97 (12 mo) to 0.98 (24 mo)) further 
supporting our use of SWATH-MS for hippocampal 
proteome quantification. The data was uploaded to the 
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Cyber-T Web server (http://cybert.ics.uci.edu/) [51], 
which implements a t-test using a Bayesian 
regularization method for quantitative mass 
spectrometry analysis and multiple tests corrections 
were employed to derive the Posterior Probabilities of 
Differential Expression (PPDE) and perform Benjamini 
and Hochberg (BH) corrections. Cutoffs for proteins 
deemed as significantly differentially expressed were p 
values ≤ 0.05, PPDE values ≥ 0.95, and BH corrected q 
values (FDR) ≤ 0.05. All correlation analysis, linear fits, 
and frequency distributions were completed using Prism 
(GraphPad Software). The protein annotation through 
evolutionary relationship (PANTHER: 
http://www.pantherdb.org/) classification system 
(version 9.0) functional classification tool was used to 
classify lists of proteins according to function via 
annotation with the Gene Ontology (GO) term 
biological processes (BP). Ingenuity Pathway Analysis 
(IPA: Ingenuity Systems; http://www.ingenuity.com/) 
Metabolic Pathways within the Canonical Pathways tool 
to determine the likelihood that the association between 
a set of focus genes in our experiment and a pathway is 
due to random chance (the smaller the right-tailed 
Fisher Exact Test p-value, the less likely that the 
association is random). 
 
Untargeted metabolome profiling. Samples were 
analyzed by HILIC ESI-Q-TOF/MS as previously 
described [52], in MS1 mode. Tissue extracts from 
hippocampus, caudoputamen, and frontal cortex 
(individual extracts pooled from both hemispheres) 
from 6 individuals at each time point (3 regions x 6 
specimen or a total of 18 samples per time point) were 
analyzed on 6550 iFunnel QTOF mass spectrometer 
(Agilent Technologies) interfaced with 1200 HPLC 
system (Agilent Technologies). No differences were 
observed between the left and right hemisphere (using 
mixed linear effect regression model), thus, due to the 
limited sample amount the final analysis (untargeted 
and targeted) as reported in results were performed on 
individual extracts pooled from both hemispheres. 
Samples were analyzed using a Luna Aminopropyl, 3 
μm, 150 mm × 1.0 mm I.D. HILIC column 
(Phenomenex). The mobile phase was composed of A = 
20 mM ammonium acetate and 20 mM ammonium 
hydroxide in 95% water and B = 95% acetonitrile [53]. 
The linear gradient elution from 100% B (0−5 min) to 
100% A (45−50 min) was applied (A = 95% H2O, B = 
95% ACN, with appropriate additives). A 10 min 
postrun was applied for HILIC, to ensure the column re-
equilibration and maintain the reproducibility. The flow 
rate was 50 μL/min, and the sample injection volume 
was 2 μL. ESI source conditions were set as follows: 
dry gas temperature 200 °C and flow 11 L/min, 
fragmentor 380 V, sheath gas temperature 300 °C and 
flow 9 L/min, nozzle voltage 500 V, and capillary 
voltage −2500 V in ESI negative mode. The instrument 
was set to acquire over the m/z range 50−1000, with the 
MS acquisition rate of 2 spectra/s. For the Auto MS/MS 
the isolation width was set as narrow (~ 1.3 m/z), with a 
MS acquisition rate of 350ms and MS/MS acquisition 
rate of 75ms. In each cycle (1.2s), 10 precursor ions 
were chosen for fragmentation at collision energy (CE) 
of 20 V and 40V. Selected precursor was excluded after 
the MS/MS data was acquired 3 times and released after 
0.15 minutes. Additional Auto LC/MS/MS analyses 
were performed using an HPLC system (1200 series, 
Agilent Technologies) coupled to TTOF 5600 (Q-TOF, 
AB Sciex), in DDA mode. In each cycle, 15 precursor 
ions were chosen for fragmentation at collision energy 
(CE) of 30 V (15 MS/MS events with product ion 
accumulation time of 50 msec each) [54] ESI source 
conditions were set as following: Ion source gas 1 as 15, 
Ion source gas 2 as 10, Curtain gas as 10, source 
temperature 550 °C, Ion Spray Voltage Floating (ISVF) 
5500V or -4500V in positive or negative modes, 
respectively. LC conditions (column, mobile phase and 
gradient) were the same as described for HILIC 
untargeted profiling.  
 
Targeted multiple pathway analysis. Quantitation of 
metabolites from multiple central core pathways was 
performed by HILIC ESI-QqQ/MS in Dynamic multiple 
reaction monitoring mode (MRM) as described in more 
details in Supplemental Information.  
 
Metabolome data processing and analysis. Raw LC/MS 
data were converted to mzXML files using ProteoWizard 
MS Convert version 3.0.7529 [55]. mzXML files were 
uploaded to XCMS Online web platform for data 
processing (https://xcmsonline. scripps.edu) including 
peak detection, retention time correction, profile 
alignment, and isotope annotation [56, 57]. Data were 
processed as a multi-group experiment and the parameter 
settings were as follows: centWave for feature detection 
(Δ m/z = 15 ppm, minimum peak width = 10 sec and 
maximum peak width = 120 sec); obiwarp settings for 
retention time correction (profStep = 1); and parameters 
for chromatogram alignment, including mzwid = 0.015, 
minfrac = 0.5 and bw = 5. The relative quantification of 
metabolite features was based on EIC (Extracted Ion 
Chromatogram) areas. One-way Analysis of Variance 
(ANOVA) and post-HOC Tukey test was used to filter 
out the significantly altered metabolite features over time 
(12 months - mature adult, 18 months - old and 24 
months - aged). The results output, including metabolite 
feature table, extracted ion chromatograms and multi-
group cloud plot, were exported directly from XCMS 
Online. One extract of hippocampus at 24 months was 
excluded from the analysis as an outlier. Mummichog 
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computational algorithm based on BioCyc pathway 
database (biocyc.org) [58] was used to accelerate 
metabolite feature filtering, characterize the biological 
activity network and predict metabolite identifications 
[59]. After filtering out the isotopes, adducts, multiple 
charged species and in-source fragments, only the 
corresponding deprotonated monoisotopic features were 
used in further analysis. Metabolite identification was 
validated using the accurate mass (within 5 ppm), 
retention time and MS/MS data. Accurate masses were 
searched against databases METLIN and HMDB. The 
identifications were made by matching the acquired 
MS/MS data for altered metabolites in brain tissue extract 
against MS/MS data recorded for standards, assembled in 
in-house developed and online available METLIN 
database (https://metlin.scripps.edu/index.php) [60, 61]. 
MS/MS matches are provided in the Supplemental 
Information (Figure S5). Mixed linear effect regression 
model was used to further test different factors (time, 
brain hemisphere, brain region) for the variation of 
identified altered metabolites in aged mice. Altered 
metabolome variation pattern was further explored using 
heat map combined with Hierarchical Cluster Analysis in 
R version 3.1.2 (gplots library). A z-transformation was 
performed on all peak areas to scale the data. 
Hierarchical clustering analysis (HCA) of metabolite 
patterns was performed using Euclidean distance matrix 
and the complete linkage method. Pathway enrichment 
analysis were performed with MetaboAnalyst a web 
server designed for comprehensive metabolomics data 
analysis [62].  
 
Metabolic drift calculation. We had 6 metabolite 
abundance values for each metabolite (6 biological 
replicates per brain regions per time point) for each age: 
12 months, 18 months and 24 months. A mean 
metabolite abundance was calculated for each 
individual metabolite for each age group. The metabolic 
drift was calculated as a log of metabolite fold change 
from old (18 and 24 months) to reference adult stage 
(12 months). To calculate the drift-variance value 
within the adult reference stage group (12 months) one 
biological replicate in that group was used as reference, 
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FBMI euthanasia and 1H MRS. Mice were anesthetized 
by inhalation of 1-2% isoflurane in oxygen and aligned in 
the water-jacketed animal holder for microwave 
irradiation in a Muromachi Microwave Fixation System 
(10 kW model). The irradiation times varied from 800 to 
820 ms at constant 4.9 kW depending on the body weight 
(g) of each mouse, as determined previously [1]. The 
brain was then isolated and split into hemispheres. Three 
regions (hippocampus, caudoputamen, midbrain and 
frontal cortex) were dissected following anatomical 
boundaries and immediately flash frozen in liquid 







































nance spectroscopy (1H MRS) was performed on post-
mortem, thawed midbrain tissues to validate the degree 
of metabolite stability by comparing post-mortem 
metabolite levels to those characterized in live animals 
done in other studies [1, 2]. Nine millimeter cubic volu-
me, single voxel localized spectra were acquired on brain 
tissue placed in perflouropolyether oil (Fomblin, Fisher 
Scientific, Pittsburg, PA) to measure metabolite signals 
using point resolved spectroscopy (PRESS) sequence. 
Spectra were acquired with a repetition time of 4 seconds, 
echo time of 50 ms, 64 averages, using a custom built 
solenoid coil on a  7 T/16 cm  Bruker  Pharmascan  MRI/ 
MRS system. Brains with increased lactate signals were 
eliminated from further analysis (Figure S1). Six speci-
mens at each time point (12, 18 and 24 months) were se-





















































































In regards to the anesthesia, mice were placed into an 
induction chamber with 1.5% isoflurane in 100% 
oxygen for 10 minutes prior to being placed into the 
holder for subsequent focused-beam microwave 
irradiation (FBMI, to provide instantaneous euthanasia 
and metabolism quenching due to the heat inactivation 
of enzymes). Within the FBMI holder, mice were free 
breathing room air. While we did not measure arterial 
PO2, we have had extension experience with isoflurane 
during rodent MRI. In our experience, breathing rate is 
typically high after induction (50-90 breaths per minute) 
and does not slow down until about 15 minutes into the 
scanning session during MRI experiments with 
continued isoflurane exposure. In addition, parallel 









































periods of anesthesia, keeping the breathing rate at 50 
pbm or greater, there is no deoxygenation of the arterial 
blood as measured by pulse oximetry and there is a 
normal physiological response to 5% CO2 including 
increased breathing rate and increased cerebral 
perfusion during scanning periods exceeding three 
hours (our unpublished data). While we have not found 
studies comparing young and old mice, one study did 
indeed find a decrease in pO2, and increase in pCO2, 
after 2-3 hours of isoflurane anesthesia, far longer than 
the short induction performed here [3]. Thus increased 
anaerobic metabolism is an unlikely consequence of a 
short period of isoflurane.  
 
Figure S2. Heatmaps showing the protein expression changes from 12‐ to 24‐months  in the mouse hippocampus
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 Figure S4. Sulfatide level changes in the aged mouse brain. Significant changes  in the  levels of specific
brain  lipids  sulfatides  (p  ≤  0.01)  are  represented  by Box‐Whisker  plots where  the  blue  colored  boxes  imply
significant metabolite depletion. Box and whisker plots display the full range of variation (whiskers:median with

















































Proteome reference library generation. The 
hippocampal protein fractions from both hemispheres of 
mice at each age were used to generate the SWATH-
MS reference spectral library that was used to extract 
quantitative levels of proteins from the hippocampus of 
12- and 24-month old mice. Protein lysates were 
prepared from each hemisphere from two mice, 12- and 
24-months old, and mixed in equal amounts. This lysate 















































digestion using the filter-aided sample preparation 
(FASP) method [4]. The peptides were desalted using 
Oasis mixed-mode weak cation-exchange (MCX) 
cartridges following the manufacturer’s protocols. The 
resulting peptides were quantified by absorbance at 205 
nm [5]. Peptides (35 μg) were fractionated into 12 
fractions from pH 3 to 10 (low-resolution kit) by 
isoelectric focusing using an Agilent 3100 OFFGEL 
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Figure S5. Matching of  tandem mass  spectrometry data acquired by autonomous  IDA  (Information Dependent Analysis  for
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 Figure  S6.  Additional  changes  in  metabolite  levels  indirectly  related  to  the  changes  in  core  pathways  as
presented in Figure 4. Box and whisker plots display the full range of variation (whiskers: median with minimum _ maximum;
boxes: interquartile range). Y‐axis is represented as a log10 of metabolite area.  
Fractionated peptides were cleaned and prepared for 
mass spectrometry using Pierce C-18 PepClean Spin 
Columns (Thermo Fisher). Samples were dehydrated 
with a Savant ISS 110 SpeedVac Concentrator (Thermo 
Fisher) and resuspended in 6 μL of 0.1% FA for LC-
MS/MS analysis. In order to generate the SWATH-MS 
reference spectral library the prepared fractions were 
subjected to traditional Data-Dependent Acquisition 
(DDA) as described previously [6]. Briefly, one 
precursor scan followed by fragmentation of the 50 
most abundant peaks was performed. Precursor peaks 
with a minimum signal count of 100 were dynamically 
excluded after two selections for 6 seconds within a 
range ± 25 mDa. Charge states other than 2-5 were 
rejected. Rolling collision energy was used. All DDA 
LC-MS/MS files were searched in unison using 
ProteinPilot as described above [6]. Combined results 
yielded a library of 456,807 spectra representing 41,515 
peptides and 4,671 proteins identified with high 
confidence (greater than 99%) that passed the global 
FDR from fit analysis using a critical FDR of 1%.  
 
Targeted validation. Quantitation of metabolites of 
interest was performed using an HPLC system (1290 
Infinity, Agilent Technologies) coupled to ion-Funnel 

















ter. It was operated in Dynamic multiple reaction 
monitoring mode (MRM), where the collision energies 
and product ions (MS2 or quantifier and qualifier ion 
transitions) were pre-optimized for each metabolite of 
interest (Table S7). Cycle time was 500 ms, and the 
total number of MRM’s was 137. ESI source conditions 
were set as following: gas temperature 225 °C, gas flow 
15 L/min, nebulizer 35 psi, sheath gas 400 °C, sheath 
gas flow 12 L/min, capillary voltage 2500V and nozzle 
voltage 0V in ESI negative mode. The analyses were 
performed on the same type of Phenomenex 
aminopropyl column as for untargeted analysis, but the 
larger size 150mm x 2mm, with the same mobile 
phases, at the 350 μL/min flow rate. Metabolites were 
targeted in a negative ionization mode, using the 
gradient from 95 % B (0-2 min) to 10% B (15 min) to 
0% B (17-20 min). A 4 min column re-equilibration 
was applied at the initial solvent composition, to 
ensure the reproducibility. The injection volume was 2 
μL for all analyzed tissue extracts. Standard compound 
mixtures were used for method optimization, 
calibration and as a quality control. The ion response 
for each standard solution was determined by 
integrating the area of the quantifier transitions listed 
in Table S7 for each compound (Agilent QQQ 



























1 Acetyl-CoA 808.1 78.9 408 75/38
2 Acetyl-glutamic acid 188.1 128 102.1 10/14 
3 Adenine 134 107 92 18/22 
4 Adenosine 266.1 134.1 107 26/40 
5 ADP 426 134.1 158.9/78.9 22/30/74 
6 alpha-ketoglutarate 145 101 57 6/10 
7 Aminoadipic acid 160.1 116.1 142.1 14/10 
  









8 AMP 346.1 78.9 96.9/134.1 46/26/42 
9 Arginine 173.1 131.1 156.1 10/10
10 ATP 505.9 158.9 408/78.9 26/22/75 
11 CDP 402 158.9 384/78.9 22/18/66 
12 Citric acid 191 111 87 6/18 
12 CMP 322 78.9 96.9 34/30 
13 CTP 481.9 158.9 384/78.9 38/22/66 
14 Cysteine sulfate 199.9 136 80.9/74 
///
10/10/14 
15 Cytidine 242.1 109 42 10/26 
16 Fructose-1,6-bisphosphate 338.9 96.9 241/78.9 14/14/74 
17 Fructose-6-phosphate 259 78.9 138.9 54/14 
18 Fumarate 115 71 27 2/10 
19 GDP 442 150 158.9/78.9 
/
26/30/75 
20 GDP-mannose 604.1 424 158.9/78.9 
/
26/34/46 
21 Glutamate 146 128 102.1 6/10 
22 Glutamine 145.1 109 127.1 10/6 
23 Glyceraldehyde-3P 168.9 150.9 96.9/78.9 6/2/18 
24 Glycerate-3P 184.9 78.9 167.1/96.9 
/
10/10/10 
25 GMP 362.1 78.9 211/133 26/14/46 
26 GTP 521.9 424 158.9/ 78.9 22/26/75 
27 Guanosine 282.1 150 133 18/30 
28 Hypoxanthine 135 92 65 14/30 
29 IMP 347 96.9 135/ 78.9 
/
22/38/74 
30 Inosine 267.1 135 108 26/46 
31 Lactate 89 43 41 10/20 
32 Malate 133 115 71 6/14 
33 Methionine 148 47 32 14/66 
34 NAD+ 662.1 540.1 158.9/ 78.9 6/50/75 
35 NADH 664.1 397 408/ 78.9 
/
30/38/75 
36 NADP+ 742.1 620 408 10/35 
37 Oxidized glutathione 611.1 306.1 272.1/143 
/
22/30/46 
38. Phosphoenol pyruvate 166.9 78.9 62.9 14/75 
39 PRPP 388.9 176.9 290.9/78.9 14/10/62 
40 Ribose-1-phosphate 229 78.9 138.9/96.9 54/10/10 
41 Saccharopine 275.1 257.1 196.1/145.1 
/
10/18/26 
42 Succinate 117 73 99 10/22 
43 Sulfoacetic acid 138.9 94.9 79.9 10/26 
44 Tryptophan 203.1 116.1 142.1 10/14 
45 Tyrosine 180.1 163 119.1 10/14 
46 UDP 402.9 158.9 111/78.9 26/18/75 
47 UDP-galactose 565.1 323 158.9/78.9 
/
22/54/75 
48 UDP-N-acetyl-glucosamine 606.1 78.9 272.9/158.9 70/34/62 
49 UMP 323 96.9 111/78.9 22/30/58
 51 Uric acid 167 124 96/41.9 
/
14/18/50 
52 Uridine 243.1 200 110 6/10 
53 UTP 482.9 158.9 384.1/78.9 34/18/74 
54 Xanthine 151 108 41.9 18/30 
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